Drugs for Lipogranulomatosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show all 32)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Lenalidomide |
Approved |
Phase 2 |
|
191732-72-6 |
216326 |
Synonyms:
1-oxo-2-(2,6-Dioxopiperidin-3-yl)-4-aminoisoindoline
3-(4-Amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione
CC-5013
CC-5013|CDC-501|Revlimid®
CDC 501
CDC-501
Celgene brand OF lenalidomide
IMID-1
|
IMiD3
IMiD3 CPD
Lenalidomida
LENALIDOMIDE
Revimid
Revlimid
SYP-1512
|
|
2 |
|
Angiogenesis Inhibitors |
|
Phase 2 |
|
|
|
3 |
|
Immunologic Factors |
|
Phase 2 |
|
|
|
4 |
|
Cetuximab |
Approved |
Phase 1 |
|
205923-56-4 |
|
Synonyms:
ABP-494
ANTI EGFR
C225
C-225
C225|Erbitux®|IMC-225|IMC-C225
CETUXIMAB
Cétuximab
CETUXIMAB (GENETICAL RECOMBINATION)
|
Cetuximabum
CMAB009
CMAB-009
ERBITUX
IMC-225
IMC-C225
MOAB C225
|
|
5 |
|
Valproic acid |
Approved, Investigational |
Phase 1 |
|
99-66-1 |
3121 |
Synonyms:
(N-C3H7)2chcooh
(S)-2-Propyl-4-pentanoate
(S)-2-Propyl-4-pentanoic acid
2 Propylpentanoic acid
2-N-PROPYL-4-PENTENOIC ACID
2-N-Propyl-N-valerate
2-N-Propyl-N-valeric acid
2-Propylpentanoate
2-PROPYL-pentanoate
2-Propylpentanoic acid
2-PROPYL-pentanoIC ACID
2-Propylvalerate
2-Propylvaleric acid
44089
4-Heptanecarboxylate
4-Heptanecarboxylic acid
A-44090
A-44090|Depakote®|Epilim®|valproate sodium
Acetate, dipropyl
Acid, propylisopropylacetic
Acid, valproic
Acide valproique
acide valproïque
Acido valproico
ácido valproico
Acidum valproicum
Alti-valproic
Apo-divalproex
Apo-valproic
Apo-valproic syrup
Avugane
Baceca
Calcium valproate
Calcium, valproate
Convulex
Convulsofin
Delepsine
Depacon
Depakene
Depakin
Depakin chrono
Depakine
Depakine chrono
Depakote
Deproic
Di-N-propylacetate
Di-N-propylacetic acid
Di-N-propylessigsaeure
Di-N-propylessigsaure
Di-n-propylessigsäure
Dipropyl acetate
Dipropylacetate
Dipropylacetic acid
Divalproex
Divalproex sodium
DOM-divalproex
Dom-valproate
DOM-valproic
Dom-valproic acid
DOM-valproic acid e.c.
Dom-valproic acid syrup
DPA
Epiject i.v.
Epilex
Epilim
|
Epival
Epival er
Ergenyl
Gen-divalproex
Kyselina 2-propylvalerova
LEP321
Magnesium valproate
Med valproic
Mylproin
Myproate
Myproic acid
N-Dipropylacetic acid
N-DPA
Novo-divalproex
Novo-valproic
Novo-valproic - ecc
Novo-valproic soft gel cap
NSC-93819
Nu-valproic
PEAC
Penta-valproic
PHL-Valproate
PHL-Valproic acid
PHL-Valproic acid e.c.
PMS-Divalproex
PMS-Valproate
PMS-Valproic acid
PMS-Valproic acid e.c.
Propylisopropylacetic acid
Propylvaleric acid
Ratio-valproic - ecc
S(-)-4-En-valproate
S(-)-4-En-valproic acid
S-2-N-Propyl-4-pentenoate
S-2-N-Propyl-4-pentenoic acid
Sandoz valproic
Savicol
Semisodium valproate
Sodium hydrogen divalproate
Sodium valproate
Sodium, divalproex
Sodium, valproate
Sprinkle
STAVZOR
Valcote
Valparin
Valproate
Valproate calcium
Valproate semisodique [French]
Valproate semisodium
Valproate sodium
Valproate, calcium
Valproate, magnesium
Valproate, semisodium
Valproate, sodium
Valproato semisodico [Spanish]
Valproatum seminatricum [Latin]
VALPROIC ACID
Valproic acid usp
Valproic acid USP24
Valproic acid, sodium salt (2:1)
Valproinsaeure
Valproinsäure
VPA
Vupral
|
|
6 |
|
Bevacizumab |
Approved, Investigational |
Phase 1 |
|
216974-75-3 |
135329020 |
Synonyms:
12-IGG1
ANTIVEGF
Anti-VEGF Humanized Monoclonal Antibody
Anti-VEGF monoclonal antibody
AVA-1
AVASTIN
Bevacizumab
BEVACIZUMAB BETA
bevacizumab-awwb
|
BI 695502
BS-503A
FKB-238
HLX04
HLX-04
R-435
RG-435
RHUMAB-
rhuMAb-VEGF
|
|
7 |
|
Sirolimus |
Approved, Investigational |
Phase 1 |
|
53123-88-9 |
5284616 6436030 |
Synonyms:
(-)-Rapamycin
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-{(2S)-1-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]propan-2-yl}-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.0(4,9)]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone
Antibiotic ay 22989
AY-22989
AY-22989|Fyarro® (sirolimus albumin-bound particles)|Rapamune®|rapamycin|WY-090217
L04AA10
NSC-226080
Perceiva
RAPA
Rapammune
|
Rapamune
Rapamycin
Rapamysin
RPM
Sirolimus
Sirolimús
Sirolimusum
SM-88 COMPONENT SIROLIMUS
WY-090217
|
|
8 |
|
Miconazole |
Approved, Investigational, Vet_approved |
Phase 1 |
|
22916-47-8 |
4189 |
Synonyms:
1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-[2-(2,4-Dichloro-benzyloxy)-2-(2,4-dichloro-phenyl)-ethyl]-1H-imidazole
Brentan
CONOFITE
Dactarin
DERMAZOLE
DUMICOAT
Esteve brand OF miconazole
florid(nitrate)|Monistat®|R-14889
Janssen cilag brand OF miconazole
Janssen-cilag brand OF miconazole
Johnston and johnston brand OF miconazole nitrate
LORAMYC
MCZ
MICATIN
|
Miconasil nitrate
Miconazol
Miconazole
Miconazole esteve brand
Miconazole janssen-cilag brand
Miconazole nitrate
Miconazolum
Monistat
MONISTAT-3
MONISTAT-DERM
Nitrate, miconasil
Nitrate, miconazole
NSC-170986
Oravig
VUSION
|
|
9 |
|
Clotrimazole |
Approved, Vet_approved |
Phase 1 |
|
23593-75-1 |
2812 |
Synonyms:
(Chlorotrityl)imidazole
1-((2-Chlorophenyl)diphenylmethyl)-1H-imidazole
1-(a-(2-Chlorophenyl)benzhydryl)imidazole
1-(alpha-(2-Chlorophenyl)benzhydryl)imidazole
1-(O-Chloro-a,a-diphenylbenzyl)imidazole
1-(O-Chloro-alpha,alpha-diphenylbenzyl)imidazole
1-(O-Chlorotrityl)imidazole
1-(O-Chloro-α,α-diphenylbenzyl)imidazole
1-(Α-(2-chlorophenyl)benzhydryl)imidazole
ABTRIM
ACTAVALL
Bay b 5097
BAY-5097
Bayer brand 1 OF clotrimazole
Bayer brand 2 OF clotrimazole
CANDIDEN
Canesten
Canesten 1-day cream combi-pak
Canesten 1-day therapy
Canesten 3-day therapy
Canesten 6-day therapy
CANESTEN AF
Canesten combi-pak 1-day therapy
Canesten combi-pak 3-day therapy
Canesten cream
CANESTEN CRM COMBI
CANESTEN INTERNAL
Canesten solution
CANESTEN VC
Canesten®|Lotrimin®
Canestine
Chlotrimazole
Clotrimaderm
Clotrimaderm cream
Clotrimazol
CLOTRIMAZOLE
Clotrimazole schering brand
Clotrimazolum
Desamix F
Empecid
FB b 5097
Fem care
FemCare
FUNGEDERM
GNF-PF-3499
Gyne lotrimin
Gyne-lotrimin
Gyne-lotrimin 3
Gyne-lotrimin 3 combination pack
Gyne-lotrimin combination pack
Gyne-lotrimin3
Gyne-lotrimin3 combination pack
|
Gynix
Kanesten
Klotrimazole
Lopac-C-6019
Lotrimax
Lotrimin
LOTRIMIN (TN)
Lotrimin af
Lotrimin af cream
Lotrimin af jock-itch cream
Lotrimin af lotion
Lotrimin af solution
Lotrimin cream
Lotrimin lotion
Lotrimin solution
Lotrisone
MASNODERM
mono-Baycuten
Monobaycuten
Mycelax
Mycelex
MYCELEX (TN)
Mycelex 7
Mycelex cream
Mycelex g
Mycelex otc
Mycelex solution
Mycelex troches
Mycelex twin pack
Mycelex: mycosporinrimazole
Mycelex-7
Mycelex-7 combination pack
Mycelex-g
MYCIL GOLD
Myclo cream
Myclo solution
Myclo spray solution
Myclo-gyne
Mycosporin
Mykosporin
Neo-zol cream
NSC-257473
Otomax
Pedisafe
Prestwick_120
PRIVACOM
Rimazole
Schering brand OF clotrimazole
Tibatin
Trimysten
Trivagizole 3
Veltrim
|
|
10 |
|
Mitogens |
|
Phase 1 |
|
|
|
11 |
|
Neurotransmitter Agents |
|
Phase 1 |
|
|
|
12 |
|
Immunoglobulins, Intravenous |
|
Phase 1 |
|
|
|
13 |
|
Anti-Bacterial Agents |
|
Phase 1 |
|
|
|
14 |
|
Anti-Infective Agents |
|
Phase 1 |
|
|
|
15 |
|
Immunoglobulins |
|
Phase 1 |
|
|
|
16 |
|
Immunoglobulin G |
|
Phase 1 |
|
|
|
17 |
|
Antifungal Agents |
|
Phase 1 |
|
|
|
18 |
|
Psychotropic Drugs |
|
Phase 1 |
|
|
|
19 |
|
Anticonvulsants |
|
Phase 1 |
|
|
|
20 |
|
Antibodies, Monoclonal |
|
Phase 1 |
|
|
|
21 |
|
Antibodies |
|
Phase 1 |
|
|
|
22 |
|
Antibiotics, Antitubercular |
|
Phase 1 |
|
|
|
23 |
|
Immunosuppressive Agents |
|
Phase 1 |
|
|
|
24 |
|
Antineoplastic Agents, Immunological |
|
Phase 1 |
|
|
|
25 |
|
Endothelial Growth Factors |
|
Phase 1 |
|
|
|
26 |
|
Vemurafenib |
Approved |
|
|
918504-65-1 |
42611257 |
Synonyms:
BRAF(V600E) KINASE INHIBITOR RO5185426
N-[3-[[5-(4-CHLOROPHENYL)-1H-PYRROLO[2,3-B]PYRIDIN-3-YL]CARBONYL]-2,4-DIFLUOROPHENYL]-1-PROPANESULFONAMIDE
PLX 4032
PLX4032
PLX-4032
PLX4032|RG7204|Zelboraf®
RG7204
|
RG-7204
RO-5185426
RO-51-85426
VEMURAFENIB
Vémurafénib
Vemurafenibum
Zelboraf
|
|
27 |
|
Choline |
Approved, Nutraceutical |
|
|
62-49-7 |
305 |
Synonyms:
(2-Hydroxyethyl)trimethyl ammonium
(2-Hydroxyethyl)trimethylammonium
(2-HYDROXYETHYL)TRIMETHYLAZANIUM
(beta-Hydroxyethyl)trimethylammonium
2-HYDROXYETHYL-TRIMETHYL-AMMONIUM
2-HYDROXYETHYL-TRIMETHYL-AZANIUM
2-Hydroxy-N,N,N-trimethylethanaminium
2-Hydroxy-N,N,N-trimethyl-ethanaminium
Bilineurine
Biocolina
Biocoline
Bitartrate, choline
Bursine
Chloride, choline
CHOLINE
Choline bitartrate
Choline cation
Choline chloride
Choline citrate
Choline hydroxide
|
CHOLINE ion
Choline O sulfate
Choline O-sulfate
Cholinum
Citrate, choline
Fagine
Hepacholine
Hormocline
Hydroxide, choline
Lipotril
N,N,N-Trimethylethanolammonium
N,N,N-Trimethylethanol-ammonium
Neocolina
N-Trimethylethanolamine
O-Sulfate, choline
Paresan
Trimethylethanolamine
Vidine
Vitamin J
|
|
28 |
|
Antimetabolites |
|
|
|
|
|
29 |
|
Hypolipidemic Agents |
|
|
|
|
|
30 |
|
Nootropic Agents |
|
|
|
|
|
31 |
|
Lipid Regulating Agents |
|
|
|
|
|
32 |
|
Gastrointestinal Agents |
|
|
|
|
|
Interventional clinical trials:
(show all 17)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
A Phase II Therapeutic Trial of the Use of Dabrafenib and Trametinib in Patients With BRAF V600E Mutation Positive Lesions in Erdheim Chester Disease |
Completed |
NCT02281760 |
Phase 2 |
Dabrafenib Mesylate;Trametinib Dimethyl Sulfoxide |
2 |
A Single-arm, Open Label, Multicenter Phase II Clinical Study in Rare Diseases to Evaluate Safety, Efficacy and PK of HLX208 for Adult Langerhans Cell Histiocytosis (LCH) and Erdheim-Chester Disease (ECD) With BRAF V600E Mutation |
Recruiting |
NCT05092815 |
Phase 2 |
HLX208 |
3 |
A First-in-Human, Open Label, Phase I/II Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HH2710 in Patients With Advanced Tumors |
Recruiting |
NCT04198818 |
Phase 1, Phase 2 |
HH2710 |
4 |
A Phase 2 Study to Assess the Safety and Efficacy of Cobimetinib in Refractory Langerhans Cell Histiocytosis, LCH-Associated Neurodegenerative Disease, and Other Histiocytic Disorders. |
Recruiting |
NCT04079179 |
Phase 2 |
Cobimetinib |
5 |
A Phase II Study of Lenalidomide for Adult Histiocyte Disorders |
Active, not recruiting |
NCT02523040 |
Phase 2 |
Lenalidomide |
6 |
Open-label, Single-arm, Phase II, Prospective, Pilot Study of Tocilizumab in Patients With Erdheim-Chester Disease |
Terminated |
NCT01727206 |
Phase 2 |
Tocilizumab |
7 |
A Phase II Therapeutic Trial of the Use of Dabrafenib and Trametinib in Patients With BRAF V600 Mutation Positive Lesions in Erdheim Chester Disease |
Withdrawn |
NCT03794297 |
Phase 2 |
Dabrafenib Mesylate;Trametinib Dimethyl Sulfoxide |
8 |
A Phase I Trial of Bevacizumab, Temsirolimus Alone and in Combination With Valproic Acid, or Cetuximab in Patients With Advanced Malignancy and Other Indications |
Active, not recruiting |
NCT01552434 |
Phase 1 |
Temsirolimus;Valproic Acid |
9 |
Long-term Outcome After Vemurafenib / BRAF Inhibitors Interruption in Erdheim-chester Disease |
Unknown status |
NCT02089724 |
|
|
10 |
Observational and Cross-Sectional Cohort Study of the Natural History and Phenotypic Spectrum of Farber Disease |
Completed |
NCT03233841 |
|
|
11 |
Clinical and Pathophysiological Investigations Into Erdheim-Chester Disease |
Completed |
NCT01417520 |
|
|
12 |
Pilot Study to Determine Uptake and Biodistribution of 18F-fluorocholine in Histiocytic Disorders by PET Imaging and Biopsy Measurement |
Completed |
NCT02608619 |
|
|
13 |
Registry for Patients With Erdheim-Chester Disease and Other Histiocytoses |
Recruiting |
NCT03329274 |
|
|
14 |
A Study to Identify the Supportive Care Needs of Caregivers of Patients With Erdheim-Chester Disease and Other Histiocytic Diseases |
Recruiting |
NCT03990428 |
|
|
15 |
International Rare Histiocytic Disorders Registry (IRHDR) |
Recruiting |
NCT02285582 |
|
|
16 |
Biomarker for Farber Disease - An International, Multicenter, Epidemiological Protocol |
Active, not recruiting |
NCT02298634 |
|
|
17 |
A Clinical, Structural, and Functional Neuroimaging Study of Cognition in Adults With Erdheim-Chester Disease, Langerhans Cell Histiocytosis, Rosai-Dorfman Disease, and Other Histiocytoses |
Active, not recruiting |
NCT03127709 |
|
|
|